ArticleBlood advances2026

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.

Haris Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.